Source: CureToday articles
The BCMA protein has become the primary target for treating multiple myeloma, resulting in longer survival and more manageable side effects.
Recent Content
- LY6E as a new prognostic biomarker of multiple myeloma-related bone disease
- Dynamic monitoring of M-protein quantification by immunotyping using capillary zone electrophoresis during the chemotherapy of patients with multiple myeloma
- Efficacy and Safety of Quadruplet Therapy in Newly Diagnosed Transplant-Eligible Multiple Myeloma: A Systematic Review and Meta-Analysis
- Nivolumab May Restore T-Cell Fitness Following CAR T-Cell Therapy in Patients With Multiple Myeloma
- Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study
- Non-relapse mortality with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma
- Prognostic and clinicopathological value of the controlling nutritional status score in patients with multiple myeloma: a meta-analysis
- What Role Does MRD Play in Multiple Myeloma Treatment Decision Making?
- Depression, anxiety prevalent among adults with lymphoma, multiple myeloma
- Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysis